Safety and tolerability of pasireotide long-acting release in acromegaly—results from the acromegaly, open-label, multicenter, safety monitoring program for treating patients who have a need to receive medical therapy (ACCESS) study

PURPOSE: Pasireotide long-acting release is a somatostatin analog that is indicated for treatment of patients with acromegaly. This analysis documents the safety of pasireotide long-acting release in patients with acromegaly enrolled in the ACCESS trial (ClinicalTrials.gov identifier: NCT01995734)....

Descripción completa

Detalles Bibliográficos
Autores principales: Fleseriu, Maria, Rusch, Elisha, Geer, Eliza B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2016
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5225222/
https://www.ncbi.nlm.nih.gov/pubmed/27896545
http://dx.doi.org/10.1007/s12020-016-1182-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5225222/
https://www.ncbi.nlm.nih.gov/pubmed/27896545
http://dx.doi.org/10.1007/s12020-016-1182-4

Ejemplares similares